TRULICITY
Drug
Lilly USA, LLC
Total Payments
$69.3M
Transactions
659,742
Doctors
92,239
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $68,555 | 3,312 | 2,279 |
| 2023 | $684,098 | 38,481 | 15,469 |
| 2022 | $2.6M | 94,400 | 38,375 |
| 2021 | $7.0M | 143,902 | 44,787 |
| 2020 | $6.9M | 55,553 | 19,266 |
| 2019 | $16.3M | 94,941 | 24,393 |
| 2018 | $20.6M | 101,639 | 28,892 |
| 2017 | $15.0M | 127,514 | 32,013 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30.6M | 31,925 | 44.2% |
| Unspecified | $25.5M | 1,813 | 36.8% |
| Food and Beverage | $9.8M | 615,025 | 14.2% |
| Consulting Fee | $1.9M | 643 | 2.7% |
| Travel and Lodging | $1.5M | 10,310 | 2.1% |
| Education | $1,340 | 26 | 0.0% |
Payments by Type
General
$43.8M
657,929 transactions
Research
$25.5M
1,813 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $13.1M | 81 |
| THE EFFECT OF DULAGLUTIDE ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES - RESEARCHING CARDIOVASCULAR EVENTS WITH A WEEKLY INCRETIN IN DIABETES - REWIND | Eli Lilly and Company | $4.4M | 25 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $3.0M | 38 |
| A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS-AWARD-PEDS- ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY | Eli Lilly and Company | $1.4M | 28 |
| A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-PEDS: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY) | Eli Lilly and Company | $1.0M | 22 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly Export S.A. Puerto Rico Branch | $917,236 | 4 |
| RELATIVE BIOAVAILABILITY OF AN INVESTIGATIONAL SINGLE DOSE OF DULAGLUTIDE AFTER SUBCUTANEOUS ADMINISTRATION BY A SINGLE DOSE PEN COMPARED TO A PREFILLED SYRINGE IN HEALTHY SUBJECTS | Eli Lilly and Company | $802,847 | 0 |
| A RANDOMIZED OPEN LABEL PARALLEL ARM STUDY COMPARING THE EFFECT OF ONCE WEEKLY DULAGLUTIDE WITH INSULIN GLARGINE ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND MODERATE OR SEVERE CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $369,466 | 4 |
| CROSSOVER STUDY COMPARING THE DULAGLUTIDE (TRULICITY) PEN AND THE SEMAGLUTIDE (OZEMPIC) PEN | Eli Lilly and Company | $230,800 | 0 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly Export S.A. Puerto Rico Branch | $66,202 | 0 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND STUDY OF EFFICACY AND SAFETY OF DULAGLUTIDE WHEN ADDED TO SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $59,271 | 9 |
| A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-PEDS: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY) | Eli Lilly Export S.A. Puerto Rico Branch | $36,645 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF TWO DOSES OF DULAGLUTIDE IN COMBINATION WITH A SINGLE ORAL ANTIHYPERGLYCEMIC MEDICATION OR AS MONOTHERAPY IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-JPN: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES - JAPAN) | Eli Lilly and Company | $33,570 | 0 |
| A RANDOMIZED DOUBLE-BLIND PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF TWO DOSES OF DULAGLUTIDE IN COMBINATION WITH A SINGLE ORAL ANTIHYPERGLYCEMIC MEDICATION OR AS MONOTHERAPY IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-JPN: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES - JAPAN) | Eli Lilly and Company | $21,990 | 0 |
| A RANDOMIZED DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS (AWARD-PEDS: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY) | Eli Lilly and Company | $17,568 | 0 |
| A RANDOMIZED, DOUBLE-BLIND STUDY WITH AN OPEN-LABEL EXTENSION COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH PLACEBO IN PEDIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS-AWARD-PEDS- ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-PEDIATRIC STUDY | Eli Lilly Export S.A. Puerto Rico Branch | $17,182 | 1 |
| THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION | Eli Lilly and Company | $14,746 | 20 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND STUDY OF EFFICACY AND SAFETY OF DULAGLUTIDE WHEN ADDED TO SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly Export S.A. Puerto Rico Branch | $3,016 | 0 |
Top Doctors Receiving Payments for TRULICITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Angelica Frias | — | Houston, TX | $23.1M | 1,432 |
| , M.D | Endocrinology, Diabetes & Metabolism | Nashville, TN | $451,843 | 606 |
| , M.D | Internal Medicine | Camp Springs, MD | $435,031 | 707 |
| , MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $432,164 | 531 |
| , M.D | Endocrinology, Diabetes & Metabolism | Albany, NY | $420,148 | 569 |
| , M.D., M.P.H | Family Medicine | New Braunfels, TX | $415,598 | 766 |
| , MD | Internal Medicine | Aliso Viejo, CA | $411,923 | 616 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $407,177 | 685 |
| , MD | Endocrinology, Diabetes & Metabolism | Port Charlotte, FL | $391,933 | 636 |
| , MD | Endocrinology, Diabetes & Metabolism | Salinas, CA | $390,696 | 614 |
| , MD | Internal Medicine | Nashville, TN | $390,121 | 612 |
| , MD | Endocrinology, Diabetes & Metabolism | Los Gatos, CA | $389,586 | 658 |
| , MD | Endocrinology, Diabetes & Metabolism | Sterling, VA | $386,930 | 704 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $375,686 | 615 |
| , D.O | Internal Medicine | Arlington, VA | $374,979 | 701 |
| , D.O | Obesity Medicine | Sisters, OR | $373,801 | 987 |
| , MD | Endocrinology, Diabetes & Metabolism | Greensboro, NC | $368,344 | 509 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $363,303 | 632 |
| , MD | Endocrinology, Diabetes & Metabolism | Williamsville, NY | $356,860 | 475 |
| , MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $354,711 | 617 |
| , M.D | Endocrinology, Diabetes & Metabolism | Southaven, MS | $354,607 | 350 |
| , MD | Endocrinology, Diabetes & Metabolism | Terre Haute, IN | $351,558 | 601 |
| , M.D | Endocrinology, Diabetes & Metabolism | Tulsa, OK | $340,678 | 500 |
| , MD | Endocrinology, Diabetes & Metabolism | Huntington, WV | $340,476 | 584 |
| , M.D | Specialist | Baltimore, MD | $335,074 | 346 |
Ad
Manufacturing Companies
- Lilly USA, LLC $43.3M
- Eli Lilly and Company $24.8M
- Eli Lilly Export S.A. Puerto Rico Branch $1.1M
Product Information
- Type Drug
- Total Payments $69.3M
- Total Doctors 92,239
- Transactions 659,742
About TRULICITY
TRULICITY is a drug associated with $69.3M in payments to 92,239 healthcare providers, recorded across 659,742 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.
Payment data is available from 2017 to 2024. In 2024, $68,555 was paid across 3,312 transactions to 2,279 doctors.
The most common payment nature for TRULICITY is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($30.6M, 44.2% of total).
TRULICITY is associated with 18 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS" ($13.1M).